PerkinElmer

Fluorescent Agents

OF

Our portfolio of Targeted, Activatable, and Vascular fluorescent agents for imaging utilizes optimized in vivo chemistries and diverse mechanisms of action to deliver breakthrough imaging data on biological targets, pathways and processes - in the context of the living system.

 

Benefits of PerkinElmer Fluorescent Agents:

  • Biological, functional and physiological information
  • Easily applied to standard animal models
  • Versatile
    • use for simultaneous monitoring of multiple molecular processes
    • custom-design a fluorescent agent using PerkinElmer tags and/or nanoparticles
  • Designed and optimized for translational in vivo imaging narrow spectrally-separated excitation/emission spectra in the NIR region
  • High fluorescence efficiency (quantum yield)
  • Biocompatible, biodegradable and excretable
  • Chemical and photo-stability in vivo
  • Compatible with a variety of in vivo imaging systems
  • Developed and optimized on PerkinElmer's optical imaging platforms

 

 

For research use only. Not for use in diagnostic procedures.

 

Products & Services (36)
Filters:

Filters :

Therapeutic Area
  • Angiogenesis (9)
  • Arthritis (15)
  • Atherosclerosis (13)
  • Bacterial infection (4)
  • Inflammation (13)
  • Oncology/Cancer (22)
  • Vascular disease (4)
Product Brand Name
  • BacteriSense (1)
  • BombesinRSense (1)
  • Cat B FAST (2)
  • Cat K FAST (1)
  • FolateRSense (1)
  • GastroSense (1)
  • Genhance (4)
  • GFR-Vivo (1)
  • HypoxiSense (1)
  • IntegriSense (3)
  • MMPSense (1)
  • OsteoSense (3)
  • ProSense (1)
  • ReninSense (1)
  • Superhance (1)
  • TLectinSense (1)
  • Transferrin-Vivo (1)
  • XenoLight (6)
Fluorescent Agent Type
  • Activatable (7)
  • Targeted (20)
  • Vascular (9)
Imaging Modality
  • Fluorescence (35)

1-12 of 36 Products & Services

Sort by

  • In vivo Fluorescent Agents

    OsteoSense 800 Fluorescent Imaging Agent

    Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications. 
    List Price : 607.00 USD
  • In vivo Fluorescent Agents

    MMPSense Fluorescent Imaging Agent

    Matrix metalloproteinases (MMPs) are calcium-dependent zinc containing endopeptidases responsible for the degradation of most of extracellular matrix proteins during organogenesis, growth and normal tissue turnover. MMPs play a role in almost every biological cell process from embryo implantation to cell death and have been implicated in a wide range of diseases including inflammation, arthritis, pulmonary disease, cancer and more.

    PerkinElmer’s MMPSense NIR activatable fluorescence agents are designed to evaluate many disease related processes including cancer progression, rheumatoid arthritis, pulmonary disease and more as well as evaluating therapeutic efficacy of potential drug candidates.

    List Price : 731.00 USD
  • In vivo Fluorescent Agents

    IntegriSense 645 Fluorescent Imaging Agent

    Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications. 
    List Price : 731.00 USD
  • In vivo Fluorescent Agents

    AngioSense 680EX Fluorescent Imaging Agent

    Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications.
    List Price : 601.00 USD
  • RediJect Probe Explorer Kit

    RediJect Bacterial Detection Fluorescent Imaging Probe (Explorer Kit)

    XenoLight RediJect Bacterial Detection Probe is a near-infrared (NIR) fluorescent agent for in vivo targeting of both Gram-positive and Gram-negative bacterial infections. 
    List Price : 154.00 USD
  • In vivo Fluorescent Agents

    ProSense Fluorescent Imaging Agent

    Proteases perform a fundamental role in protein regulation. Altered activity of lysosomal cathepsins, a class of protease, can indicate many disease-related processes, such as those involved in cancer, inflammation, arthritis, cardiovascular and many others. The ability to detect and quantify normal as well as altered protease cathepsin activity in vivo allows the progress and severity of these disease states to be tracked and interrogated over time. PerkinElmer’s ProSense® imaging agents are protease activatable NIR fluorescent probes that are optically silent in their intact state and become highly fluorescent following protease-mediated cleavage and activation. ProSense is available in 3 formats; 680, 750 EX, and 750 FAST.
    Price Range : 601.00 USD - 710.00 USD
  • In vivo Fluorescent Agents

    BacteriSense 645 Fluorescent Imaging Agent

    Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications.  
    List Price : 1047.00 USD
  • In vivo Fluorescent Agents

    IntegriSense 750 Fluorescent Imaging Agent

    Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications. 
    List Price : 717.00 USD
  • RediJect 2-DG Fluorescent Imaging Probe (Standard kit)

    XenoLight RediJect 2-DeoxyGlucosone (DG) 750 is a fluorescent imaging probe for in vivo targeting of tumors that typically exhibit elevated glucose uptake rate in comparison to surrounding tissues. To achieve maximum glucose targeting and enhanced tumor uptake, the probe has been designed to contain four 2-DG molecules per dye molecule.  
    List Price : 495.00 USD
  • In vivo Fluorescent Agents

    TLectinSense 680 Fluorescent Imaging Agent

    Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications. 
    List Price : 631.00 USD
  • RediJect Probe Standard Kit

    RediJect Bacterial Detection Fluorescent Imaging Probe (Standard kit)

    XenoLight RediJect Bacterial Detection Probe is a near-infrared (NIR) fluorescent agent for in vivo targeting of both Gram-positive and Gram-negative bacterial infections. 
    List Price : 490.00 USD
  • In vivo Fluorescent Agents

    OsteoSense 680EX Fluorescent Imaging Agent

    Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications. 
    List Price : 607.00 USD
  • Jump to:
Business Insights (4)
Filters:

1-4 of 4 Business Insights

Sort by

  • Application Note

    Vascular Imaging Probes For Oncology and Inflammation Using the IVIS Spectrum

    Optical-based in vivo imaging of vascular changes and vascular leak is an emerging modality for studying altered physiology in a variety of different cancers and inflammatory states. A number of fluorescent imaging probes that circulate with the blood, but have no target selectivity, have been used to detect tumor leakiness as an indication of abnormal tumor vasculature. Inflammation is also characterized by distinct vascular changes, including vasodilation and increased vascular permeability, which are induced by the actions of various inflammatory mediators. This process is essential for facilitating access for appropriate cells, cytokines, and other factors to tissue sites in need of healing or protection from infection. This application note investigates the use of three fluorescent imaging probes, to detect and monitor vascular leak and inflammation in preclinical mouse breast cancer models.

  • Application Note

    Imaging Hepatocellular Liver Injury using NIR-labeled Annexin V

    Drug induced liver injury (DILI) is a major reason for late stage termination of drug discovery research projects, highlighting the importance of early integration of liver safety assessment in the drug development process. A technical approach for in vivo toxicology determination was developed using Acetaminophen (APAP), a commonly used over-the-counter analgesic and antipyretic drug, to induce acute hepatocellular liver injury.

  • Application Note

    Multiplex 2D Imaging of NIR Molecular Imaging Agents on the IVIS SpectrumCT and FMT 4000

    Epifluorescence (2D) imaging of superficially implanted mouse tumor xenograft models offers a fast and simple method for assessing tumor progression or response to therapy. This approach for tumor assessment requires the use of near infrared (NIR) imaging agents specific for different aspects of tumor biology, and this Application Note highlights the ease and utility of multiplex NIR fluorescence imaging to characterize the complex biology within tumors growing in a living mouse.

  • Poster

    Combined efficacy & toxicity imaging following acute 5-FU treatment of HT-29 tumor xenografts

    Cancer chemotherapy can produce severe side effects such as suppression of immune function and damage to heart muscle, gastrointestinal tract, and liver. If serious enough, tissue injury can be a major reason for late stage termination of drug discovery research projects, so it is becoming more important to integrate safety/toxicology assessments earlier in the drug development process. There are a variety of traditional serum markers, tailored mechanistically to specific tissues, however there are no current non-invasive assessment tools that are capable of looking broadly at in situ biological changes in target and non-target tissue induced by chemical insult.